Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
4.410
+0.030 (0.68%)
At close: Dec 19, 2025, 4:00 PM EST
4.409
-0.001 (-0.03%)
After-hours: Dec 19, 2025, 7:48 PM EST
CPIX Revenue
Cumberland Pharmaceuticals had revenue of $8.29M in the quarter ending September 30, 2025, a decrease of -8.73%. This brings the company's revenue in the last twelve months to $41.28M, up 12.21% year-over-year. In the year 2024, Cumberland Pharmaceuticals had annual revenue of $37.87M, down -4.26%.
Revenue (ttm)
$41.28M
Revenue Growth
+12.21%
P/S Ratio
1.56
Revenue / Employee
$453,608
Employees
91
Market Cap
65.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
| Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
| Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
| Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
| Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
| Dec 31, 2019 | 34.39M | 5.04M | 17.19% |
| Dec 31, 2018 | 29.34M | -11.81M | -28.69% |
| Dec 31, 2017 | 41.15M | 8.12M | 24.60% |
| Dec 31, 2016 | 33.03M | -493.49K | -1.47% |
| Dec 31, 2015 | 33.52M | -3.38M | -9.17% |
| Dec 31, 2014 | 36.90M | 4.87M | 15.22% |
| Dec 31, 2013 | 32.03M | -16.82M | -34.44% |
| Dec 31, 2012 | 48.85M | -2.29M | -4.48% |
| Dec 31, 2011 | 51.14M | 5.27M | 11.48% |
| Dec 31, 2010 | 45.88M | 2.34M | 5.37% |
| Dec 31, 2009 | 43.54M | 8.46M | 24.13% |
| Dec 31, 2008 | 35.08M | 7.01M | 24.98% |
| Dec 31, 2007 | 28.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CPIX News
- 11 days ago - CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - PRNewsWire
- 6 weeks ago - Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH - PRNewsWire
- 7 weeks ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE - PRNewsWire
- 2 months ago - CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO - PRNewsWire
- 2 months ago - RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - PRNewsWire
- 2 months ago - CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. - PRNewsWire
- 2 months ago - CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO - PRNewsWire